CD229/SLAMF3/Lymphocyte Antigen 9 Antibody (249936)

• Reactivity: Hu
• Applications: WB, Flow, CyTOF-ready
• Clone: 249936
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

CD229/SLAMF3/Lymphocyte Antigen 9 Antibody (249936) Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant human CD229/SLAMF3
  Lys48-Lys454
  Accession # Q9HBG7
• Specificity: Detects human CD229/SLAMF3 in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross‑reactivity with recombinant mouse CD229 is observed.
• Source: N/A
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Gene: LY9
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • Flow Cytometry 2.5 ug/10^6 cells
  • Western Blot 1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CD229/SLAMF3/Lymphocyte Antigen 9 Antibody (249936)

• CD229 antigen
• CD229
• cell-surface molecule Ly-9
• hly9
• Ly9
• lymphocyte antigen 9Cell surface molecule Ly-9
• mLY9
• SLAMF3
• T-lymphocyte surface antigen Ly-9

Background

CD229, also known as Ly9 and SLAMF3, is a 120 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family (1). Mature human CD229 consists of a 407 amino acid (aa) extracellular domain (ECD) with two Ig‑like V-set and two Ig‑like truncated C2-set domains. It also shows a 22 aa transmembrane segment, and a 179 aa cytoplasmic domain with two immunoreceptor tyrosine-based switch motifs ITSMs (2, 3). The ECD of human CD229 shares 57%‑59% aa sequence identity with mouse and rat CD229. Within the first two Ig‑like domains that are common to all SLAM proteins, human CD229 shares 24%‑39% aa sequence identity with human 2B4, BLAME, CD2F-10, CD84, CRACC, NTB-A, and SLAM. Alternate splicing generates two additional isoforms that lack the juxtamembrane Ig‑like domain or short cytoplasmic region (2). CD229 is expressed on T and B cells, thymocytes, and more weakly on NK cells (2‑6). Homophilic binding between CD229 molecules is mediated by the N-terminal Ig‑like domain (7). Human and mouse CD229 exhibit cross-species binding (7). Antigen stimulation of lymphocytes induces CD229 clustering to sites of T cell‑B cell contact (7). Two tyrosines in the cytoplasmic domain are required for association of CD229 with the adaptor proteins AP-2 (μ2 chain) and GRB-2 and both are required for CD229 internalization (8, 9). In addition, there are two ITSMs which mediate phosphorylation-dependent CD229 association with SAP and SHP-2 (10). These four tyrosine-containing motifs are intact in the described CD229 splice variants. CD229 knockout mice show minimally impaired immune responses, suggesting functional redundancy with other molecules (11).

1. Bhat, R. et al. (2006) J. Leukoc. Biol. 79:417.
2. de la Fuente, M.A. et al. (2001) Blood 97:3513. 
3. Sandrin, M.S. et al. (1992) J. Immunol. 149:1636.
4. Romero, X. et al. (2004) Tissue Antigens 64:132. 
5. Hogarth, P.M. et al. (1980) Immunogenetics 11:65. 
6. Mathieson, B.J. et al. (1980) J. Immunol. 125:2127.
7. Romero, X. et al. (2005) J. Immunol. 174:7033.
8. Del Valle, J.M. et al. (2003) J. Biol. Chem. 278:17430.
9. Martin, M. et al. (2005) J. Immunol. 174:5977.
10. Sayos, J. et al. (2001) Blood 97:3867.
11. Graham, D.B. et al. (2006) J. Immunol. 176:291.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CD229/SLAMF3/Lymphocyte Antigen 9 Antibody (MAB1898)(2)

Publications using MAB1898

• AJ Collier, SP Panula, JP Schell, P Chovanec, A Plaza Reye, S Petropoulo, AE Corcoran, R Walker, I Douagi, F Lanner, PJ Rugg-Gunn Comprehensive Cell Surface Protein Profiling Identifies Specific Markers of Human Naive and Primed Pluripotent States Cell Stem Cell, 2017-03-23;0(0):. 3/23/2017 [PMID: 28343983]
• Atanackovic D, Panse J, Hildebrandt Y, Jadczak A, Kobold S, Cao Y, Templin J, Meyer S, Reinhard H, Bartels K, Lajmi N, Zander AR, Marx AH, Luetkens T, Bokemeyer C, Kroger N Surface molecule CD229 as a novel target for the diagnosis and treatment of multiple myeloma. Haematologica, 2011-05-23;0(0):. 2011-05-23 [PMID: 21606160] (IHC-P, Western Blot, Human)

Bioinformatics

• Gene Symbol: LY9
• Uniprot:
  • Q9HBG7()